Travere Therapeutics Inc (NASDAQ: TVTX) kicked off on Friday, down -3.10% from the previous trading day, before settling in for the closing price of $18.09. Over the past 52 weeks, TVTX has traded in a range of $5.12-$19.25.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 3.07% over the last five years. While this was happening, its average annual earnings per share was recorded -136.13%. With a float of $75.34 million, this company’s outstanding shares have now reached $75.37 million.
The firm has a total of 380 workers. Let’s measure their productivity. In terms of profitability, gross margin is 82.2%, operating margin of -212.99%, and the pretax margin is -215.65%.
Travere Therapeutics Inc (TVTX) Insider Activity
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Travere Therapeutics Inc is 1.51%, while institutional ownership is 115.45%. The most recent insider transaction that took place on Oct 04 ’24, was worth 589,101. In this transaction Director of this company sold 40,000 shares at a rate of $14.73, taking the stock ownership to the 51,000 shares. Before that another transaction happened on Oct 04 ’24, when Company’s Officer proposed sale 40,000 for $13.65, making the entire transaction worth $546,000.
Travere Therapeutics Inc (TVTX) Earnings and Forecasts
In the latest quarterly report, which was put into the public domain on 6/30/2024, the organization reported 1.97 earnings per share (EPS), higher than consensus estimate (set at -0.14) by 2.11. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.55 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -136.13% per share during the next fiscal year.
Travere Therapeutics Inc (NASDAQ: TVTX) Trading Performance Indicators
Take a look at Travere Therapeutics Inc’s (TVTX) current performance indicators. Last quarter, stock had a quick ratio of 2.99. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 7.55.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.84, a number that is poised to hit -0.64 in the next quarter and is forecasted to reach -1.19 in one year’s time.
Technical Analysis of Travere Therapeutics Inc (TVTX)
Analysing the last 5-days average volume posted by the [Travere Therapeutics Inc, TVTX], we can find that recorded value of 0.99 million was lower than the volume posted last year of 1.4 million. As of the previous 9 days, the stock’s Stochastic %D was 47.98%. Additionally, its Average True Range was 1.05.
During the past 100 days, Travere Therapeutics Inc’s (TVTX) raw stochastic average was set at 86.18%, which indicates a significant increase from 67.85% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 71.24% in the past 14 days, which was higher than the 64.05% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $13.61, while its 200-day Moving Average is $9.29. Now, the first resistance to watch is $18.10. This is followed by the second major resistance level at $18.66. The third major resistance level sits at $19.01. If the price goes on to break the first support level at $17.19, it is likely to go to the next support level at $16.84. Should the price break the second support level, the third support level stands at $16.28.
Travere Therapeutics Inc (NASDAQ: TVTX) Key Stats
The company with the Market Capitalisation of 1.34 billion has total of 76,129K Shares Outstanding. Its annual sales at the moment are 145,240 K in contrast with the sum of -111,400 K annual income. Company’s last quarter sales were recorded 54,120 K and last quarter income was -70,410 K.
